Golden State Medical Supply Inc. Initiates Class II Recall of Prasugrel Tablets Over Failed Dissolution
Golden State Medical Supply Inc. has initiated a U.S. nationwide Class II recall for 2,601 bottles of PRASUGREL TABLETS, 5 mg, due to failed dissolution specifications. This voluntary action, impacting multiple lots, signals critical quality control deficiencies. Procurement and regulatory teams must assess immediate supply chain risks for this antiplatelet medication and reinforce supplier qualification protocols to mitigate future disruptions and ensure product efficacy.
FDA Class II Recall: Golden State Medical Supply Inc.'s Prasugrel Tablets Fail Dissolution
Golden State Medical Supply Inc., based in Camarillo, CA, United States, has initiated a voluntary Class II recall, designated D-0287-2025, for its PRASUGREL TABLETS, 5 mg. This critical antiplatelet medication, distributed U.S. nationwide in 30-count bottles (NDC 51407-444-30 and 51407-445-30), was recalled on March 5, 2025, due to a failure in dissolution specifications. A total of 2,601 bottles across seven specific lots—GS059908, GS060228, GS060709, GS061233, GS061704, GS062158, and GS062405—are affected, all bearing an expiration date of April 30, 2026. This Class II classification by the FDA indicates that the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. For procurement directors, this necessitates an immediate assessment of inventory and supply chain exposure to these specific lots of Prasugrel. Regulatory affairs heads must understand the implications of a Class II recall, which signals a significant quality deviation impacting product performance. Supply chain VPs should evaluate potential disruptions and shortages for this critical generic medication.
Commercial and Clinical Implications of Prasugrel Dissolution Failure
The failure of dissolution specifications for PRASUGREL TABLETS, 5 mg, is a critical quality attribute deficiency with significant commercial and clinical implications. Dissolution testing is fundamental to ensuring that the active pharmaceutical ingredient, Prasugrel Hydrochloride, is released from the tablet at the appropriate rate and extent, which is essential for proper absorption and bioavailability in the patient's body. A failure in this specification means the drug may not be adequately absorbed, potentially leading to reduced therapeutic efficacy. Prasugrel is vital for preventing thrombotic events in patients with acute coronary syndromes, making its consistent performance paramount for patient safety. For formulators and distributors, this directly impacts product quality and patient outcomes. Business development executives must consider the reputational damage associated with distributing a product that fails such a critical quality attribute. Regulatory heads face increased scrutiny on post-market surveillance. Procurement directors must ensure their quality agreements with suppliers explicitly cover dissolution testing parameters and demand certificates of analysis for each lot. Regulatory affairs teams need to prepare for potential inquiries regarding product efficacy and safety, especially given Prasugrel's critical therapeutic role. Supply chain VPs should review their quality control checkpoints for incoming raw materials and finished products to prevent similar issues.
Mitigating Supply Chain Risk and Enhancing Quality Assurance Post-Recall
This voluntary recall by Golden State Medical Supply Inc. underscores the imperative for robust internal quality systems and stringent supplier qualification processes across the pharmaceutical industry. While firm-initiated, such events highlight the ongoing regulatory scrutiny on product quality. For instance, recent FDA actions, such as the Class II recall of Essential Wellness Pharma's Progesterone Injection for sterility issues or the FDA hearing regarding Amgen's Tavneos, demonstrate a consistent focus on drug quality and safety across various therapeutic areas. Procurement directors should initiate a comprehensive review of their supplier qualification programs, focusing on manufacturers of critical generic drugs like Prasugrel. This includes conducting thorough audits of quality management systems, manufacturing processes, and testing protocols. Supply chain VPs must diversify sourcing strategies where possible to build resilience against such disruptions, ensuring continuity of supply for essential medications. Regulatory affairs heads should ensure their quality management systems are robust enough to detect and respond to quality deviations proactively, minimizing the risk of distributing non-compliant products. This event reinforces the need for stringent quality control throughout the pharmaceutical supply chain in the United States to safeguard patient health and maintain market integrity.